Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058606 | 1.00 | SMPD3 (0.46) | SMPD3HRH3SLC6A9JAK2GRM1 | |
| SCHEMBL23246758 | 0.82 | PDE10A (0.47) | SMPD3JAK2RETADRA1AUBE2T | |
| SCHEMBL15205869 | 0.82 | PDE10A (0.47) | SMPD3JAK2RETADRA1AUBE2T | |
| SCHEMBL15205870 | 0.82 | PDE10A (0.47) | SMPD3JAK2RETADRA1AUBE2T | |
| SCHEMBL2791625 | 0.82 | SMPD3 (0.52) | SMPD3JAK2RETADRA1AUBE2T | |
| SCHEMBL19775600 | 0.82 | ADRA1A (0.52) | HRH3SLC6A9GRM1GPR119ADRA1A | |
| SCHEMBL18022508 | 0.82 | ADRA1A (0.52) | HRH3SLC6A9GRM1GPR119ADRA1A | |
| SCHEMBL22581845 | 0.81 | GPR119 (0.52) | SMPD3HRH3SLC6A9GRM1GPR119 | |
| SCHEMBL19574003 | 0.80 | HDAC6 (0.47) | SMPD3SLC6A9KMT2A | |
| SCHEMBL20180775 | 0.80 | HDAC6 (0.47) | SMPD3SLC6A9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312995-A1 | BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS | SCHERING CORPORATION (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312995-A1 | BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS | SCHERING CORPORATION (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312995-A1 | BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS | GPR119, FFAR2, FFAR1 | SMPD3 894/4885HRH3 2067/4885SLC6A9 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.